Drug profile · INN
deuruxolitinib phosphate
LEQSELVI
deuruxolitinib phosphate (LEQSELVI) is a tyrosine-protein kinase jak1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — deuruxolitinib phosphate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
deuruxolitinib phosphate (LEQSELVI) is a tyrosine-protein kinase jak1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Tyrosine-protein kinase JAK1 inhibitor
Primary target: Tyrosine-protein kinase JAK1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is deuruxolitinib phosphate?
deuruxolitinib phosphate (LEQSELVI) is a tyrosine-protein kinase jak1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for deuruxolitinib phosphate?
LEQSELVI is a marketed brand name for deuruxolitinib phosphate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of deuruxolitinib phosphate?
deuruxolitinib phosphate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.